Breast Mesh/Internal Bra Overview

A growing number of breast mesh and internal bra products have been associated with painful complications and reconstructive failures after surgery. These devices were sold to plastic surgeons as supportive scaffolds, which women were told would help keep the implants in place, improve shape, and strengthen weakened tissue.

Over the past several years, mesh scaffolds like Phasix, GalaFLEX, Strattice and similar products have been widely used by plastic surgeons to reinforce weakened breast tissue and improve implant positioning. These products were originally cleared for soft-tissue reinforcement in hernia repair but were later adopted in breast procedures without formal FDA review or clinical trials specific to the breast.

Without any breast-specific approval, manufacturers began selling mesh to plastic surgeons for its supposed cosmetic and structural benefits, which in return were used for breast augmentations and reconstructive surgeries.

Now, as studies document higher rates of infection, implant displacement and revision surgery tied to these internal bra techniques, those early FDA warnings are being reconsidered as a direct reflection of what the clinical data is showing.

The agency made its stance clear years ago that no mesh device has been approved for breast implantation, and that all use in reconstruction or augmentation is off-label. Yet manufacturers continued presenting these products as internal support systems, allowing an unapproved application to gain widespread acceptance, despite a lack of breast-focused safety evaluation.

As more women report complications and undergo revision surgeries, many are now seeking legal representation and exploring potential breast mesh lawsuits, alleging that manufacturers continued selling these devices being used for internal bra procedures despite FDA warnings and no approval for use in breast tissue.

U.S. Food & Drug Administration (FDA) has not approved any surgical mesh products for use in breast surgeries.

The U.S. Food & Drug Administration (FDA) has not approved any surgical mesh products for use in breast surgeries, including reconstruction and augmentation.

Despite this, some manufacturers promoted or allowed their mesh products to be used “off-label” in breast procedures, meaning the devices were implanted in ways that were not properly cleared or tested for safety in the breasts.

Many breast mesh products were originally cleared for hernia or general soft-tissue repair through the FDA’s 510(k) process. The off-label use of these devices has led to reports of infection, capsular contracture, mesh breakdown, and revision surgeries among women who underwent breast reconstruction or cosmetic augmentation.

Despite FDA warnings dating back to 2021, manufacturers have continued to sell mesh implants as “internal bras” for breast reconstruction and augmentation procedures, even though the products have never been approved as safe or effective for use during breast surgery, and have been linked to reports of painful injuries and complications.

In 2023, the FDA issued a letter tied to labeling updates for several mesh products used for soft-tissue reinforcement.

In that letter, FDA warns that, although it is aware of increased mesh use in breast surgeries, no surgical mesh is cleared or approved for breast augmentation or reconstruction, and the benefit-risk profile in this setting remains undefined.

Additionally, in December 2025, several plastic surgeons issued internal-bra warnings cautioning that mesh products used in breast lifts and augmentations may offer little proven benefit while exposing patients to serious risks, including infection, inflammation, deformity and failed reconstruction.

Why the Breast Mesh/Internal Bra may Fail

Internal bra mesh has been used in an effort to reinforce tissue and support breast implants, but reports have raised concerns about how some products perform once implanted. Mesh materials originally cleared for hernia repair or general soft tissue reinforcement were later used in the breast, a setting with different movement and tissue characteristics, where some reports suggest the materials may not perform as intended.

Over time, several patterns of breast mesh failure have been reported:

• Premature degradation: Absorbable meshes, like those made from P4HB polymers, can dissolve too quickly, leaving the implant unsupported before healing is complete.
• Loss of tensile strength: Mesh fibers can stiffen, stretch, or weaken under constant strain, causing the material to lose its intended shape.
• Poor tissue integration: If the mesh fails to incorporate into the surrounding tissue, it can detach from the implant pocket or fold on itself, leading to uneven support.
• Inflammatory breakdown: The body may recognize mesh fibers as foreign material, triggering inflammation that erodes tissue and interferes with healing.
• Mechanical stress and fatigue: Daily motion, exercise, or muscle contraction from the chest wall can cause repetitive strain, pulling the mesh away from fixation points.

These mechanical and biological failures often start gradually but can compromise the breast’s shape and support over time. When the mesh no longer holds its position, the implant can shift, the reconstruction can collapse, or scar tissue can form around distorted mesh fibers, making corrective surgery difficult.

While marketed as innovative or absorbable scaffolds, internal bra meshes were never approved to endure the long-term mechanical stress of the breast, raising serious concerns about their durability and safety.

Breast Mesh Complication Rates

Scientific studies reveal concerning complication rates that are fueling the litigation. A 2021 study found a total complication rate of 34% within six months of breast surgery with mesh, with about 13% of patients requiring implant removal.

A 2024 review found reoperation rates near 10% and implant loss in roughly 3% of cases associated with synthetic mesh use in breast surgeries.

A 2023 meta-analysis found infection rates of approximately 5%, seroma around 5%, skin necrosis approximately 5.5%, and implant loss around 4%.

The scope of potential harm is significant given the number of breast surgeries performed annually in the United States. There are approximately 100,000 breast reconstruction surgeries and more than 300,000 breast augmentation surgeries per year in the US.

Women who have undergone breast augmentation, breast lift procedures, implant-based breast reconstruction, or revision surgeries using surgical mesh may be affected by these complications.